CoChat

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Background No treatment options are available for patients with metastatic colorectal cancer that progresses after all approved standard therapies, but many patients maintain a good performance status and could be candidates for further therapy. An international phase 3 trial was done to assess the multikinase inhibitor regorafenib in these patients. Methods We did this trial at 114 centres in 16 countries. Patients with documented metastatic colorectal cancer and progression during or within 3 months after the last standard therapy were randomised (in a 2:1 ratio; by computer-generated randomisation list and interactive voice response system; preallocated block design (block size six); stratified by previous treatment with VEGF-targeting drugs, time from diagnosis of metastatic disease, and geographical region) to receive best supportive care plus oral regorafenib 160 mg or placebo once daily, for the first 3 weeks of each 4 week cycle. The primary endpoint was overall survival. The study sponsor, participants, and investigators were masked to treatment assignment. Efficacy analyses were by intention to treat. This trial is registered at ClinicalTrials.gov, number NCT01103323. Findings Between April 30, 2010, and March 22, 2011, 1052 patients were screened, 760 patients were randomised to receive regorafenib (n=505) or placebo (n=255), and 753 patients initiated treatment (regorafenib n=500; placebo n=253; population for safety analyses). The primary endpoint of overall surv…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(12)61900-x

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 17 references

Cited by

See all 2,895

Metadata

Authors
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., Adenis, A., Tabernero, J., Yoshino, T., Lenz, H.-J., Goldberg, R. M., Sargent, D. J., Cihon, F., Cupit, L., Wagner, A., & Laurent, D.
Affiliations
  • Mayo Clinic (US)
  • KU Leuven (BE)
  • Ospedale Policlinico San Martino (IT)
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
  • Azienda Ospedaliera Universitaria Pisana (IT)
  • Cliniques Universitaires Saint-Luc (BE)
  • Institut Sainte Catherine (FR)
  • Università Cattolica del Sacro Cuore (IT)
  • Centre Oscar Lambret (FR)
  • Universitat Autònoma de Barcelona (ES)
  • National Cancer Center Hospital East (JP)
  • USC Norris Comprehensive Cancer Center (US)
  • The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Corresponding author
Cutsem, Eric Van
Venue
The Lancet
Publisher
Elsevier BV
Published
2013-01
Volume
381
Issue
9863
Pages
303-312
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2147834058
Cited by
2,895
References
17
Citations by year
2026: 144 · 2025: 210 · 2024: 260 · 2023: 216 · 2022: 212 · 2021: 211 · 2020: 218 · 2019: 239 · 2018: 195 · 2017: 222 · 2016: 197 · 2015: 234 · 2014: 204 · 2013: 123
FWCI
89.91
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • DIAL (Catholic University of Leuven) (submittedVersion)
Funders
  • Bayer Fund
  • Bayer HealthCare
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords
metastatic colorectal cancer, regorafenib, multikinase inhibitor, second-line therapy, best supportive care, overall survival, hand-foot skin reaction, treatment-related adverse events, CORRECT trial, oral anticancer drugs, diarrhea, neutropenia
MeSH terms
Aged, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Phenylurea Compounds, Pyridines, Colorectal Neoplasms, Survival Rate, Disease-Free Survival, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(12)61900-x
The paper
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., Adenis, A., Tabernero, J., Yoshino, T., Lenz, H.-J., Goldberg, R. M., Sargent, D. J., Cihon, F., Cupit, L., Wagner, A., & Laurent, D. (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(12)61900-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.